Moreau P, Attal M, Hulin C, et al. Phase 3 randomized study of daratumumab + bortezomib/thalidomide/dexamethasone (D-VTD) versus VTD in transplant-eligle newly diagnosed multiple myeloma: part 1 CASSIOPEIA results. 24th Congress of EHA, abstract S145.
Profylactisch itacitinib verlaagt incidentie cytokine release syndroom na immuun-effectorceltherapie
mei 2025 | Lymfoom